Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Black Diamond Therapeutics, Inc. (BDTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
Docs: "Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update"
06/30/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "BLACK DIAMOND THERAPEUTICS, INC. 15,000,000 Shares of Common Stock Underwriting Agreement",
"Black Diamond Therapeutics, Inc."
06/30/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/29/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update"
04/04/2023 ARS Form ARS - Annual Report to Security Holders:
04/04/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/04/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
Docs: "Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update"
12/19/2022 8-K Quarterly results
12/12/2022 8-K Quarterly results
11/23/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update"
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
07/08/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/07/2022 8-K Quarterly results
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/11/2022 8-K Quarterly results
04/28/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/25/2022 8-K Investor presentation
Docs: "Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment",
"Corporate Presentation of the Company, furnished herewith"
04/14/2022 SC 13G/A BB BIOTECH AG reports a 11% stake in Black Diamond Therapeutics, Inc.
04/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors"
03/17/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/17/2022 10-K Annual Report for the period ended December 31, 2021
03/17/2022 8-K Quarterly results
Docs: "Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update"
02/11/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy